Abstract
Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Current Alzheimer Research
Title: IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Volume: 7 Issue: 7
Author(s): A. Zambrano, C. Otth, R.B. Maccioni and I.I. Concha
Affiliation:
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Abstract: Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Export Options
About this article
Cite this article as:
Zambrano A., Otth C., Maccioni R.B. and Concha I.I., IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499011
DOI https://dx.doi.org/10.2174/156720510793499011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Radioligands for the Imaging of α7 Nicotinic Acetylcholine Receptors with Positron Emission Tomography
Current Drug Targets Editorial [Hot topic: Alzheimers Disease Drug Discovery: Aβ and Beyond (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research Neuroinflammation: Microglial Activation During Sepsis
Current Neurovascular Research Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Is Formaldehyde the Missing Link in AD Pathology? The Differential Aggregation of Amyloid-Beta with APOE Isoforms In Vitro
Current Alzheimer Research Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Current Medicinal Chemistry Early Development of Symptomatic Drugs in AD: A Systematic Review of the Use of Biomarkers
CNS & Neurological Disorders - Drug Targets Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis
Current Drug Targets Meet Our Editorial Board Member
Current Alzheimer Research Common Themes in RNA Subcellular Transport, Stress Granule Formation and Abnormal Protein Aggregation
Current Chemical Biology Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry Experimental Rodent Models of Vascular Dementia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research